Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients U… (NCT05879159) | Clinical Trial Compass
RecruitingNot Applicable
Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection
United States36 participantsStarted 2023-10-05
Plain-language summary
To learn if an accelerated recovery program can shorten the length of hospital stay in patients having minimally invasive liver surgery.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Tumor amenable to MIS Kawaguchi-Gayet grade I hepatectomy (see figure 1 below)
* No evidence of cirrhosis (based on imaging, evidence of portal hypertension, clinical features, or laboratory results)
* No significant cardiopulmonary disease that would prevent patients from undergoing MIS resection
* Ability to stay within 50 miles of medical center for immediate postop period
* Age of 18 years or above - because no adverse event data are currently available on enhanced recovery and early discharge after hepatic resection for patients \<18 years of age, children are excluded from this study
* Ability to understand and the willingness to sign a written informed consent document
* Non-English-speaking patients are eligible for participation
Exclusion Criteria:
Patients who will be excluded include those with:
* Tumors NOT amenable to MIS Kawaguchi-Gayet grade I hepatectomy
* Tumors not amenable to MIS or Robotic-assisted surgical resection
* Evidence of Cirrhosis on imaging, clinically, or lab testing
* Inability to stay within 50 miles of the Cancer Center in the immediate post-operative period
* Age below 18 years
* Inability to consent for trial/protocol
* Patients who are pregnant
What they're measuring
1
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Timeframe: through study completion; an average of 1 year.